Status:
RECRUITING
The Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients
Lead Sponsor:
Cairo University
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
This clinical trial aims to evaluate the effect of dexmedetomidine in Sepsis-Associated Acute Kidney Injury in critically ill patients by answering the following questions: 1. What is dexmedetomidine...
Detailed Description
Recently, it has been confirmed that dexmedetomidine has an organ protective effect, including the nervous system, heart, lungs, kidneys, liver, and small intestine. These properties allow dexmedetomi...
Eligibility Criteria
Inclusion
- Age \>21 years old
- Patients with sepsis who develop AKI within 48 hours during ICU stay
- Need for sedation due to the need for mechanical ventilation (MV) (both invasive and non- invasive) within 48 hours of AKI
Exclusion
- Contraindications to dexmedetomidine including any of the following: severe bradycardia (heart rate (HR) \< 50 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block unless a pacemaker is inserted
- Acute myocardial ischemia
- Mean arterial blood pressure \< 50 mmHg despite adequate resuscitation and vasopressor therapy at the time of enrollment
- Pregnancy or lactation
- Duration of dexmedetomidine infusion \< 24 hours
- Severe valvular heart disease
- Active seizures during this ICU admission requiring benzodiazepines
- Proven or suspected traumatic brain injury, intracranial hemorrhage, stroke, or spinal cord injury
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT06570187
Start Date
October 1 2024
End Date
October 1 2026
Last Update
October 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt